A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

International Journal of Cancer

Volumn 138, Issue 1, 2016, Pages 195-205

  Arcaroli, John J ^a   Tai, W M ^a   Mcwilliams, Ryan ^a   Bagby, Stacey ^a   Blatchford, Patrick J ^a   Varella Garcia, Marileila ^a   Purkey, Alicia ^a   Quackenbush, Kevin S ^a   Song, Eun Kee ^a   Pitts, Todd M ^a   Gao, Dexiang ^a   Lieu, Chris ^a   Mcmanus, Martine ^a   Tan, Aik Choon ^a   Zheng, Xianxian ^b   Zhang, Qin ^b   Ozeck, Mark ^b   Olson, Peter ^b   Jiang, Zhi Qin ^c   Kopetz, Scott ^c   Jimeno, Antonio ^a   Keysar, Stephen ^a   Eckhardt, Gail ^a   Messersmith, Wells A ^a   more..

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b PFIZER INC   (United States)

^c EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

biomarker; colorectal cancer; Notch1

Indexed keywords

ANTINEOPLASTIC AGENT; JAGGED1; NOTCH1 RECEPTOR; PF 06293622; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; JAG1 PROTEIN, HUMAN; JAG1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN JAGGED 1; SERRATE JAGGED PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE DUPLICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NOTCH1 GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL PREDICTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; COPY NUMBER VARIATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BIOMARKERS, TUMOR; CALCIUM-BINDING PROTEINS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; GENE DUPLICATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JAGGED-1 PROTEIN; MALE; MEMBRANE PROTEINS; MICE; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, NOTCH1; SERRATE-JAGGED PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944277142     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29676     Document Type: Article

References (34)

1. Siegel R, Desantis C, Jemal A., Colorectal cancer statistics, 2014. CA: Cancer J Clin 2014; 64: 104-17.
2. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
3. Arcaroli JJ, Quackenbush KS, Purkey A, et al., Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a gamma-secretase inhibitor, in a preclinical colorectal explant model. Br J Cancer 2013; 109: 667-75.
4. Fischer M, Yen WC, Kapoun AM, et al., Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011; 71: 1520-5.
5. Hoey T, Yen WC, Axelrod F, et al., DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5: 168-77.
6. van Es JH, van Gijn ME, Riccio O, et al., Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435: 959-63.
7. Nakamura T, Tsuchiya K, Watanabe M., Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol 2007; 42: 705-10.
8. Noah TK, Shroyer NF., Notch in the intestine: Regulation of homeostasis and pathogenesis. Annu Rev Physiol 2013; 75: 263-88.
9. Pannuti A, Foreman K, Rizzo P, et al., Targeting Notch to target cancer stem cells. Clin Cancer Res 2010; 16: 3141-52.
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al., Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-15.
11. van Es JH, Clevers H., Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005; 11: 496-502.
12. Zolkiewska A., ADAM proteases: Ligand processing and modulation of the Notch pathway. Cell Mol Life Sci 2008; 65: 2056-68.
13. Fre S, Huyghe M, Mourikis P, et al., Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435: 964-8.
14. Sikandar SS, Pate KT, Anderson S, et al., NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010; 70: 1469-78.
15. Arcaroli JJ, Powell RW, Varella-Garcia M, et al., ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a gamma-secretase inhibitor and irinotecan in colorectal cancer. Mol Oncol 2012; 6: 370-81.
16. Chu D, Li Y, Wang W, et al., High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol 2010; 17: 1337-42.
17. Chu D, Wang W, Xie H, et al., Notch1 expression in colorectal carcinoma determines tumor differentiation status. J Gastrointest Surg 2009; 13: 253-60.
18. Zhang Y, Li B, Ji ZZ, et al., Notch1 regulates the growth of human colon cancers. Cancer 2010; 116: 5207-18.
19. Rubio-Viqueira B, Jimeno A, Cusatis G, et al., An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12: 4652-61.
20. Dangles-Marie V, Pocard M, Richon S, et al., Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features. Cancer Res 2007; 67: 398-407.
21. Kim MH, Kim HB, Yoon SP, et al., Colon cancer progression is driven by APEX1-mediated upregulation of Jagged. J Clin Invest 2013; 123: 3211-3230.
22. Sonoshita M, Aoki M, Fuwa H, et al., Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 2011; 19: 125-37.
23. Bertotti A, Migliardi G, Galimi F, et al., A molecularly annotated platform of patient-derived xenografts («xenopatients») identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-23.
24. Song EK, Tai WM, Messersmith WA, et al., Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer 2015; 136: 1967-75.
25. Migliardi G, Sassi F, Torti D, et al., Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012; 18: 2515-25.
26. Anderson RT, Keysar SB, Bowles DW, et al., The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther 2013; 12: 1994-2005.
27. Micel LN, Tentler JJ, Tan AC, et al., Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Mol Cancer Ther 2015; 14: 317-25.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
29. Qiu M, Peng Q, Jiang I, et al., Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett 2013; 328: 261-70.
30. O'Neil J, Grim J, Strack P, et al., FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204: 1813-24.
31. Leong KG, Niessen K, Kulic I, et al., Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007; 204: 2935-48.
32. Rodilla V, Villanueva A, Obrador-Hevia A, et al., Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 2009; 106: 6315-20.
33. Santagata S, Demichelis F, Riva A, et al., JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004; 64: 6854-7.
34. Arcaroli JJ, Touban BM, Tan AC, et al., Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res 2010; 16: 4165-77.